China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation agreement with the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMB, CAMS). The collaboration aims to develop novel vaccines using new technologies for the prevention and control of emerging infectious diseases. No financial details were disclosed.
Agreement Details
The cooperation includes the following key areas:
- Establishing the “Institute of Medical Biology – BCHT Joint Laboratory,” which will be listed and announced by both units.
- Conducting cooperation in scientific research projects, with specific research projects subject to separate cooperation agreements.
- IMB providing technical consulting services required by BCHT, with a separate technical consulting service agreement to be signed based on the consulting content.
- Jointly filing for national, provincial, and ministerial level scientific research projects, with specific application projects to be signed separately.
- Conducting academic exchanges and cultivating R&D talents in the cooperation fields.
- With the permission of both parties, the resources of the joint laboratory can be used to carry out the research work of their own projects.
Strategic Implications
This five-year research agreement between Changchun BCHT Biotechnology and IMB CAMS represents a significant step in advancing vaccine development for emerging infectious diseases. By combining the expertise of BCHT in biotechnology with the research capabilities of IMB CAMS, the collaboration aims to accelerate the development of novel vaccines and improve public health outcomes. This partnership is expected to enhance the companies’ positions in the global vaccine market and contribute to the broader goal of combating infectious diseases.-Fineline Info & Tech
